Table 1 Baseline Characteristics of the Study Population
Characteristics | pCR (n=24) | Non pCR (n=95) | P Value |
|---|---|---|---|
Age (y) | |||
≤50 | 12 | 48 | 0.963 |
>50 | 12 | 47 | |
Baseline maximum Tumor diameter (mm) | |||
<20 | 0 | 2 | 0.592 |
20-50 | 16 | 51 | |
>50 | 8 | 42 | |
Clinical T stage | |||
cT1 | 0 | 4 | 0.261 |
cT2 | 14 | 38 | |
cT3 | 5 | 36 | |
cT4 | 5 | 17 | |
Clinical N stage | |||
cN0 | 0 | 0 | 0.062 |
cN1 | 4 | 40 | |
cN2 | 10 | 26 | |
cN3 | 10 | 29 | |
Receptor status | |||
ER(+) | 7 | 67 | <0.001* |
ER(-) | 17 | 28 | |
PR(+) | 2 | 44 | <0.001* |
PR(-) | 22 | 51 | |
HER-2 | |||
(+) | 11 | 40 | 0.742 |
(-) | 13 | 55 | |
Ki67% | |||
≤20% | 2 | 45 | <0.001* |
>20% | 22 | 50 | |
molecular subtypes | |||
Luminal A | 0 | 11 | <0.001* |
Luminal B1 | 1 | 37 | |
Luminal B2 | 5 | 18 | |
HER2 | 6 | 22 | |
triple negative | 12 | 7 | |
Menopausal status | |||
Postmenopausal | 12 | 42 | 0.611 |
Premenopausal | 12 | 53 | |
Histological type | |||
Invasive ductal carcinoma | 24 | 91 | 0.582 |
Other | 0 | 4 | |
Neoadjuvant treatment protocol | |||
TC | 1 | 1 | 0.197 |
FEC-T | 1 | 1 | |
TEC | 18 | 82 | |
EC-T | 3 | 10 | |
Other | 1 | 1 | |